Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
This grant funds the identification and validation of targets for small molecules, biologics, and combination products, as well as preliminary product or lead series identification.
About this program
The Catalyze grant program supports innovative research aimed at the development of small molecules, biologics, and combination products. It focuses on the critical early stages of product definition, including target identification and validation, which are essential for advancing new therapeutic options. This grant is designed for researchers and organizations involved in the biopharmaceutical sector who are looking to explore and validate new therapeutic targets and lead compounds. Eligible applicants can include academic institutions, nonprofit organizations, and small businesses engaged in biomedical research. The program encourages collaboration among various stakeholders in the healthcare and pharmaceutical industries to foster innovation and expedite the development of new therapies. The grant does not allow for clinical trials, emphasizing the importance of foundational research in the product development pipeline.
Eligibility
Academic institutions, nonprofit organizations, small businesses engaged in biomedical research.